(NASDAQ: KPTI) Karyopharm Therapeutics's forecast annual revenue growth rate of 13.52% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 30.24%, and while it is forecast to beat the US market's average forecast revenue growth rate of 12.13%.
Karyopharm Therapeutics's revenue in 2026 is $146,621,000.On average, 7 Wall Street analysts forecast KPTI's revenue for 2026 to be $3,137,526,362, with the lowest KPTI revenue forecast at $2,910,484,947, and the highest KPTI revenue forecast at $3,279,965,931. On average, 6 Wall Street analysts forecast KPTI's revenue for 2027 to be $4,015,525,678, with the lowest KPTI revenue forecast at $3,462,778,498, and the highest KPTI revenue forecast at $4,725,682,191.
In 2028, KPTI is forecast to generate $4,857,461,474 in revenue, with the lowest revenue forecast at $3,972,204,090 and the highest revenue forecast at $5,801,463,839.